Children - Articles - Page 2 | CARLAT PUBLISHING

The Effect of Age and Pubertal Stage on Mental Health in Gender-Incongruent Youths

May 20, 2021

John Raiss, MD. Dr. Raiss has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

When is the best time to begin gender affirming medical care (GAMC) with respect to addressing the mental health status of children and adolescents with Gender Dysphoric Disorder? Should we begin Hormone Replacement Therapy early or wait until the adolescent is older? This research update will help you grapple with this very public debate.

EXPERT Q&A

Duty to Warn? Debating Antidepressant Suicidality

October 30, 2020

Martha J. Ignaszewski, MD and Glen Spielmans, PhD

Martha J. Ignaszewski, MD
Fellow, University of California, San Francisco

Glen Spielmans, PhD
Professor of Psychology, Metropolitan State University, St. Paul, MN

Dr. Ignaszewski and Dr. Spielmans have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

For 16 years, since the FDA black box warning about suicidality with antidepressants, our community has been quoting data that downplays this concern. We were wrong. We were deceived. Antidepressants can be lifesaving, but there really is a duty to warn. Drs. Martha Ignazewski and Glen Speilmans talk with us about what went on and how to talk about it with our families.

Transcranial Magnetic Stimulation (TMS) for Depression in Children and Adolescents

June 11, 2019

With concerns about both safety and efficacy surrounding antidepressant use in children and adolescents, we are always looking for safe, effective treatments for our patients. Transcranial Stimulation (TMS) has been around for many years, and its use in youth is expanding. We examine the evidence of efficacy and potential side effects in youth and adolescent populations.

Medications for Depression

June 11, 2019

Martha J. Ignaszewski, MD

Martha J. Ignaszewski, MD

Chief Fellow, Clinical Fellow in Psychiatry at Boston Children’s Hospital

Dr. Ignaszewski has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this QA, we review the findings of placebo- controlled trials done over the past 10 years on depression in kids and the discuss the current recommendations for medication treatment of depression in children and adolescents.

Practical Approaches to Vetting Clinical Research

June 11, 2019

Darren B. Courtney, MD, FRCPC

Darren B. Courtney, MD, FRCPC

Staff Psychiatrist for the Youth Addictions and Concurrent Disorders Service at the Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada

Dr. Courtney has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this QA, we discuss how to use the PICOT method to efficiently frame the clinical questions that arise in everyday practice. We also examine the hierarchy in terms of the types of studies that are most useful for the busy clinician to look at and provide a corresponding table covering the categories of evidence for clinical practice.

FDA Approves Adhansia XR

June 11, 2019

Talia Puzantian, PharmD, BCPP and Joshua Feder, MD

Talia Puzantian, PharmD, BCPP Joshua Feder, MD Drs. Puzantian and Feder have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this article we discuss a newly FDA-approved formulation for ADHD. Adhansia XR, is a new formulation of extended-release methylphenidate approved by the FDA for the treatment of ADHD in patients 6 years and older.

First Non-Drug Treatment Approved by FDA for Treating Children With ADHD

June 11, 2019

Talia Puzantian, PharmD, BCPP and Joshua Feder, MD

Talia Puzantian, PharmD, BCPP Joshua Feder, MD Drs. Puzantian and Feder have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In the article we discuss the effectiveness and safety of the first non-drug treatment for ADHD in kids. The FDA has recently granted medical device approval for its external Monarch Trigeminal Nerve Stimulation (eTNS) System for treating kids with ADHD ages 7–12 who are not currently taking medications.

Prescribing Patterns for Children With Anxiety Disorders

June 11, 2019

Pavan Madan, MD.

Pavan Madan, MD. Dr. Madan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Anxiety disorders are some of the most common conditions we encounter in children and adolescents, and clinicians employ a variety of medications to treat them. This study examined prescribing patterns for the initial treatment of pediatric anxiety.

Steroid-Induced Psychosis in the Pediatric Population

June 11, 2019

Ahhan Nazeer, MD.

Ahhan Nazeer, MD. Dr. Nazeer has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Although childhood psychosis is a rare disorder, an accurate diagnosis is crucial. This article analyzes the results of a 2019 case study of steroid-induced psychosis in a pediatric patient.

Risk of Psychosis With Stimulants in ADHD Patients

June 11, 2019

Pavan Madan, MD

Pavan Madan, MD Dr. Madan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

As of 2007, the FDA requires stimulant manufacturers to warn of possible psychosis with stimulant use. This article analyzes the results of a 2019 study comparing the risk of psychosis between methylphenidate and amphetamine classes of medications.